Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thurman Smith

Physician Assistant, Medical Fayetteville, AR Physician Assistant

NPI 1851723019 CMS profile 10543107

3317 N Wimberly Dr, Fayetteville, AR 72703

Open in the dashboard

General payments

$8,136

96 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thurman Smith of Fayetteville, AR is reported in the CMS Open Payments database as having received $8,136 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,896 58
2024 General $754 8
2023 General $132 6
2022 General $1,351 13
2021 General $1,002 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thurman Smith
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Thurman Smith were reported at $4,896. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Thurman Smith Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,002 $156 $41–$563 $132
2022 $1,351 $185 $55–$649 $149
2023 $132 $199 $58–$717 $160
2024 $754 $206 $62–$740 $164
2025 $4,896 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Saluda Medical Americas, Inc. $2,969 33 payments
  2. Medtronic, Inc. $2,056 31 payments
  3. Pacira Pharmaceuticals Incorporated $1,636 11 payments
  4. Boston Scientific Corporation $1,322 13 payments
  5. Vertex Pharmaceuticals Incorporated $49 2 payments
  6. KCI USA, Inc $43 3 payments
  7. SPR Therapeutics, Inc $24 1 payment
  8. Flexion Therapeutics, Inc. $20 1 payment
  9. Bioventus LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $5,138 22 payments
  2. Food and Beverage $2,998 74 payments
Products named General payments · program years 2021–2025
  1. Evoke $2,969 33 payments
  2. INTELLIS ADAPTIVESTIM $1,600 19 payments
  3. WaveWriter Alpha Prime 16 $1,223 7 payments
  4. Iovera System $919 6 payments
  5. Iovera $769 7 payments
  6. INCEPTIV $456 12 payments
  7. JOURNAVX $49 2 payments
  8. PREVENA $43 3 payments
  9. SPRINT PNS System $24 1 payment
  10. GENERAL PAIN MANAGEMENT $22 1 payment
  11. Other $140 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

892

Median for Physician Assistant: 241

Drug cost

$7,946

Median for Physician Assistant: $4,110

Branded share of claims

2.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 229 $2,280
Lidocaine Generic 16 $1,649
Tramadol Hcl Generic 162 $898
Pregabalin Generic 40 $873
Meloxicam Generic 173 $523
Cyclobenzaprine Hcl Generic 53 $438
Baclofen Generic 74 $351
Diclofenac Sodium Generic 21 $308
Methocarbamol Generic 21 $199
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $138

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$70,597

Of which drugs: $3,008

Medicare patients

471

Average age 74

Services billed

9,361

286 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Depression 32%
Diabetes 30%
Chronic kidney disease 24%
Osteoporosis 21%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 89 7,680 $774
Injection, methylprednisolone acetate, 80 mg J1040 Office 16 19 $85
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 13 $48
Injection, ketorolac tromethamine, per 15 mg J1885 Office 17 32 $18

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $5
$5 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record